Trim 25% of CL at market to 75-80% of benchmark; hard stop at $82.70
Underweight at 75-80% of benchmark is the synthesis: the Aggressive wins the directional argument (structural 200 SMA breakdown confirmed), the Conservative wins the carry argument ($3.5B FCF, 62-year dividend streak, 0.32 beta), and the Neutral calibrates the magnitude (25% trim, not 50%). The 25% trim at market captures the asymmetric risk-reward the bear thesis identifies without over-sizing into an alpha ceiling that will clip the payoff regardless of how right the directional call turns out. Execution certainty at $87.50 is prioritized over waiting for $90.58 SMA resistance that may never materialize in a 0.32 beta name with broken momentum. Hard stop architecture at $82.70 preserves capital if the structural break accelerates, while mechanical re-engagement triggers at $88.40 and $90.58 allow upside participation on Q3 earnings or divestiture catalysts.
| Position | Action |
|---|---|
| Current position at benchmark weight | Trim 25% at market ($87.50 reference), executed over 1-3 trading sessions in tranches, reaching 75-80% of benchmark consumer staples weight |
| Confirmed close below $84.74 (lower Bollinger Band) on volume >5M | Trim an additional 25% of remaining position, downgrading to defensive Underweight at 50-55% sizing |
| Confirmed close below $82.00 with volume >5M | Exit residual entirely; wait for $80-82 structural floor defense before re-engaging |
| Income-only mandate | Trim only 5-7% to reach ~93-95% of benchmark weight (preserve 2.47% dividend yield and 0.32 beta as portfolio ballast) |
Colgate-Palmolive is a misunderstood compounder at an operating inflection point where fundamental momentum has disconnected from sentiment, creating a risk-adjusted buying opportunity at lower-band technical support.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 86.96 | bearish |
| close_50_sma | 90.45 | bearish |
| close_200_sma | 87.50 | bearish |
| rsi | 32.22 | bearish |
| macd | -1.32 / -1.10 / -0.22 | bearish |
| boll_middle | 88.40 | bearish |
| boll_upper | 92.05 | neutral |
| boll_lower | 84.74 | neutral |
| atr | 1.65 | neutral |
| vwma | 87.56 | bearish |
| close | 85.32 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $90.58 (50 SMA) with positive MACD histogram
Then: Upgrade to Overweight at 80% of benchmark
Q2 2026 operating momentum: Revenue accelerating and gross margins expanding simultaneously — the holy grail of operating leverage — empirically falsifies the bear's margin compression thesis.
↩ rebuts: “Bear's 'margin compression' thesis”
· concedes: Bear is right that we shouldn't aggressively size into a confirmed downtrend — the recommendation is initiating a position with a defined risk framework, not an 'all-in' bet; The technical downtrend is real and the 200 SMA break is real — but these are lagging indicators of price action already largely played out
Colgate-Palmolive is a defensive laggard with deteriorating fundamentals, a hostile macro backdrop, and a confirmed technical downtrend—the market has correctly priced in the risks, and the bull case requires too many simultaneous tailwinds to justify initiating a long position.
· concedes: 0.32 beta and $3.5B FCF prevent catastrophic downside in tail-risk scenario; Dividend provides a floor under shares at 2.47% yield; Mean-reversion bounces off lower Bollinger Band can produce 3-5% tactical upside; HOLD (with bearish lean) is the recommendation—not a full SELL—due to downside protection
→ vs conservative: Dividend King record (60 years, 1895 unbroken) does not protect against multiple compression; treating the 2.47% yield floor as a guarantee against drawdown is a fundamental misread of staples multiples in a higher-for-longer regime where the 20.8x P/E faces 10-15% compression risk
→ vs conservative: Waiting for a 'cleaner signal' means buying the dead-cat bounce into 88.40 resistance and praying it holds—exactly what the 25-50% trim is designed to avoid
→ vs neutral: Q3 prints late October—between now and then the October 20 ex-dividend date creates mechanical drag, so neutral analyst's 'wait until Q3' exposes to a known sequence: mechanical drag followed by potential guidance cut if Q3 disappoints on NA oral-care softness and Haleon shelf-share migration
→ vs neutral: Q2 validation thesis is contradicted by price action: stock dropped from 92 to 85.32 during Q2 print window; September 18 candle at 10.84M shares (2.3x normal) shows institutions exiting into 'good' news, not buying it
Support: 84.74 · 82.7 · 81.34 · 73.22 | Resistance: 86.96 · 87.5 · 88.4 · 90.45 · 92.05
CL is in a confirmed short-term downtrend with price trading below all three major moving averages (bearish full stack). RSI at 32.22 is approaching but not yet at oversold levels (30), and MACD remains bearish with no bullish crossover signal. Price is testing the Bollinger lower band at $84.74; a break below could target $82–$83. VWMA at $87.56 above price confirms broad-selling participation in the decline. The report's final recommendation is HOLD, with invalidation of the bearish thesis occurring on a daily close back above $88.40 on volume.
Market Cap
$68.01 B
P/E (TTM)
33.59x
Forward P/E
20.80x
EPS (TTM)
$2.54
Forward EPS
$4.10
Dividend Yield
2.47%
Beta
0.323
Revenue FY2024
$20,101 M
Revenue FY2025
$20,382 M
Revenue TTM (2026-Q2)
$21,047 M
Revenue CAGR (4-year)
~3.2%
Net Income FY2024
$2,889 M
Net Income FY2025
$2,132 M
Normalized EPS FY2025
~$3.48
Diluted EPS FY2024
$3.51
Diluted EPS FY2025
$2.63
Gross Margin FY2024
60.5%
Gross Margin FY2025
60.1%
Gross Margin TTM
~60.4%
Gross Margin Q2 2026
61.5%
Operating Margin FY2024
21.5%
Operating Margin FY2025
20.8%
Operating Margin TTM
20.97%
EBITDA FY2024
$4,853 M
EBITDA FY2025
$3,956 M
EBITDA TTM
$4,983 M
Total Assets
$16.79 B
Total Liabilities
$16.22 B
Total Stockholders' Equity
$236 M
Total Debt
$7.86 B
Long-Term Debt
$7.82 B
Cash & Equivalents
$1.37 B
Net Debt
$6.49 B
Net Debt FY2022
$7.99 B
Net Debt FY2023
$7.58 B
Net Debt FY2024
$6.85 B
Net Debt FY2025
$6.70 B
Goodwill + Intangibles
$4.60 B
Treasury Stock
~$28.9 B
ROE
2.67%
ROA
15.84%
FCF FY2023
$3,040 M
FCF FY2024
$3,546 M
FCF FY2025
$3,634 M
FCF TTM
$3.46 B
FCF Margin
~16.4%
Dividends Paid FY2025
$1,823 M
Buybacks FY2025
$1,210 M
Total Shareholder Returns FY2022-2025
over $12 B
Net Debt / EBITDA
~1.3x
Current Ratio
1.026
Price/Book
288.24x
PEG Ratio
1.57
Impairment Charge FY2025
$929 M
Impairment Charge FY2022
$721 M
50-Day MA
$90.52
200-Day MA
$88.20
52-Week High
$99.33
52-Week Low
$74.55
Q2 2026 Revenue
$5,361 M
Q2 2026 EPS
$0.86
Effective Tax Rate FY2025
~26.1%
Strengths
Concerns
Colgate-Palmolive operates as a global consumer staples leader with flagship brands including Colgate, Palmolive, and Hill's Pet Nutrition, serving markets in over 200 countries. The company generates approximately $21B in annual revenue with gross margins expanding to 61.5% in Q2 2026, reflecting strong pricing power and easing input costs, while maintaining operating margins around 21%. The balance sheet demonstrates conservative leverage with Net Debt/EBITDA of ~1.3x, and the company has returned over $12B to shareholders cumulatively from 2022–2025 through dividends and buybacks, supporting its 60+ year dividend growth streak, despite a depressed TTM EPS of $2.54 caused by a $929M one-time impairment charge in FY2025.
Macro: Rates shock repricing the dominant macro theme: 10Y Treasury at highest since 2007, 30Y highest since 2004, with 97% implied probability of zero Fed rate cuts in 2026 (per Polymarket). US recession odds only 10%, so this is not a growth scare — it's a hawkish-repricing event. Bond proxies with stretched duration hit hardest; tech/AI sold off with yield spike. Thursday partial reversal on Trump–Xi summit optimism and reports of Strait of Hormuz deal progress (oil ~$100/bbl). Geopolitical overlay: Saudi Aramco halted crude supply to European refiners after Red Sea pipeline attack; Russia–Ukraine drone escalation with Moscow refinery hit. Trade risk centered on Sept 24 Trump–Xi summit covering tariffs, Taiwan, Iran, AI — two-way outcome. Higher-for-longer yield regime structurally favors Consumer Staples as bond proxies, but CL's 6-month relative return (+1.9% vs S&P +18.4%) shows the bond-substitute trade is failing because company-specific issues dominate. Defensive demand intact given low recession odds.